You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 23, 2024

CANASA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Canasa, and when can generic versions of Canasa launch?

Canasa is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Canasa

A generic version of CANASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.

  Sign Up

Drug patent expirations by year for CANASA
Drug Prices for CANASA

See drug prices for CANASA

Drug Sales Revenue Trends for CANASA

See drug sales revenues for CANASA

Recent Clinical Trials for CANASA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SandozPhase 3
Axcan PharmaPhase 3
Forest LaboratoriesPhase 3

See all CANASA clinical trials

Pharmacology for CANASA
Drug ClassAminosalicylate
Paragraph IV (Patent) Challenges for CANASA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CANASA Suppository mesalamine 1000 mg 021252 1 2013-05-24

US Patents and Regulatory Information for CANASA

CANASA is protected by two US patents.

Patents protecting CANASA

Mesalamine suppository
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Mesalamine suppository
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie CANASA mesalamine SUPPOSITORY;RECTAL 021252-002 Nov 5, 2004 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Abbvie CANASA mesalamine SUPPOSITORY;RECTAL 021252-002 Nov 5, 2004 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Abbvie CANASA mesalamine SUPPOSITORY;RECTAL 021252-001 Jan 5, 2001 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CANASA

See the table below for patents covering CANASA around the world.

Country Patent Number Title Estimated Expiration
Japan 2013514979 ⤷  Sign Up
Mexico 2012006902 SUPOSITORIO DE MESALAMINA. (MESALAMINE SUPPOSITORY.) ⤷  Sign Up
South Korea 20120104604 MESALAMINE SUPPOSITORY ⤷  Sign Up
European Patent Office 2512443 SUPPOSITOIRE DE MÉSALAMINE (MESALAMINE SUPPOSITORY) ⤷  Sign Up
Singapore 181169 MESALAMINE SUPPOSITORY ⤷  Sign Up
South Africa 201204422 MESALAMINE SUPPOSITORY ⤷  Sign Up
Canada 2784772 SUPPOSITOIRE DE MESALAMINE (MESALAMINE SUPPOSITORY) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.